429 related articles for article (PubMed ID: 6349250)
21. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
22. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.
Takei F; Levy JG; Kilburn DG
J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160
[TBL] [Abstract][Full Text] [Related]
23. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
24. Restoration of impaired T cell functions in tumor-bearing mice by the administration of interleukin 1.
Yamashita U; Shirakawa F
Jpn J Cancer Res; 1987 Mar; 78(3):270-8. PubMed ID: 3106283
[TBL] [Abstract][Full Text] [Related]
25. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
26. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.
Fuji H; Iribe H
Cancer Res; 1986 Nov; 46(11):5541-7. PubMed ID: 3489524
[TBL] [Abstract][Full Text] [Related]
27. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
28. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment.
Hanna N; Schneider M
J Immunol; 1983 Feb; 130(2):974-80. PubMed ID: 6848604
[TBL] [Abstract][Full Text] [Related]
30. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells.
Suzuki R; Handa K; Itoh K; Kumagai K
J Immunol; 1983 Feb; 130(2):981-7. PubMed ID: 6600260
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
32. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
33. Accessory cell function in tumor-bearing mice and effects of Corynebacterium parvum.
Okuda S; Taniguchi K; Kubo C; Nomoto K
J Natl Cancer Inst; 1982 Dec; 69(6):1293-7. PubMed ID: 6292563
[TBL] [Abstract][Full Text] [Related]
34. Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity.
Nakazaki Y; Tani K; Lin ZT; Sumimoto H; Hibino H; Tanabe T; Wu MS; Izawa K; Hase H; Takahashi S; Tojo A; Azuma M; Hamada H; Mori S; Asano S
Gene Ther; 1998 Oct; 5(10):1355-62. PubMed ID: 9930341
[TBL] [Abstract][Full Text] [Related]
35. Suppression of cell-mediated antitumor immunity by complete Freund's adjuvant.
Koyama S; Yoshioka T; Sakita T
Cancer Res; 1982 Aug; 42(8):3215-9. PubMed ID: 6980047
[TBL] [Abstract][Full Text] [Related]
36. Murine natural antitumor antibodies. III. Interferon treatment of a natural killer-resistant lymphoma: augmentation of natural antibody reactivity and susceptibility to in vivo natural resistance.
Miller VE; Pohajdak B; Greenberg AH
J Natl Cancer Inst; 1983 Aug; 71(2):377-84. PubMed ID: 6576195
[TBL] [Abstract][Full Text] [Related]
37. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.
Habu S; Fukui H; Shimamura K; Kasai M; Nagai Y; Okumura K; Tamaoki N
J Immunol; 1981 Jul; 127(1):34-8. PubMed ID: 7240748
[TBL] [Abstract][Full Text] [Related]
38. Differential natural killer cell reactivity against T cell lymphomas by cells from normal or stimulated mice.
Tai A; Burton RC; Warner NL
J Immunol; 1980 Apr; 124(4):1705-11. PubMed ID: 6965957
[TBL] [Abstract][Full Text] [Related]
39. Rat natural killer cell activity against lymphoid and nonlymphoid tumor cells and normal rat cell lines.
Rees RC; Reynolds CW; Herberman RB
Cancer Res; 1983 Sep; 43(9):4248-52. PubMed ID: 6871862
[TBL] [Abstract][Full Text] [Related]
40. [Defects in cell-mediated and humoral immunity in tumor-bearing mice. Evidence and characterization of suppressor cells ].
Siegl E; Günther J; Schulze HA; Brock J
Allerg Immunol (Leipz); 1981; 27(3):153-61. PubMed ID: 6214936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
